Medpace (NASDAQ:MEDP) Given New $362.00 Price Target at Robert W. Baird

Medpace (NASDAQ:MEDP) had its price objective increased by Robert W. Baird from $354.00 to $362.00 in a research note published on Monday,Benzinga reports. Robert W. Baird currently has a neutral rating on the stock.

MEDP has been the topic of a number of other reports. William Blair restated an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. TD Cowen cut their price target on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Truist Financial decreased their price objective on shares of Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a report on Monday, October 14th. Finally, Redburn Atlantic initiated coverage on shares of Medpace in a research note on Monday, October 14th. They issued a “buy” rating and a $404.00 target price for the company. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Medpace currently has an average rating of “Hold” and an average target price of $381.44.

Medpace Price Performance

MEDP opened at $350.37 on Monday. The company has a market capitalization of $10.89 billion, a P/E ratio of 30.68, a P/E/G ratio of 1.77 and a beta of 1.36. Medpace has a fifty-two week low of $286.76 and a fifty-two week high of $459.77. The firm’s fifty day moving average price is $340.33 and its two-hundred day moving average price is $354.73.

Hedge Funds Weigh In On Medpace

Several large investors have recently bought and sold shares of MEDP. State Street Corp boosted its holdings in Medpace by 7.2% during the third quarter. State Street Corp now owns 752,957 shares of the company’s stock worth $251,337,000 after buying an additional 50,312 shares during the last quarter. Geode Capital Management LLC boosted its stake in Medpace by 7.6% during the 3rd quarter. Geode Capital Management LLC now owns 628,054 shares of the company’s stock worth $209,885,000 after acquiring an additional 44,371 shares during the last quarter. Wellington Management Group LLP grew its holdings in Medpace by 36.0% during the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after purchasing an additional 109,886 shares during the period. Clearbridge Investments LLC increased its stake in Medpace by 55.1% in the second quarter. Clearbridge Investments LLC now owns 403,892 shares of the company’s stock valued at $166,343,000 after purchasing an additional 143,481 shares in the last quarter. Finally, American Capital Management Inc. raised its holdings in Medpace by 2.6% in the third quarter. American Capital Management Inc. now owns 380,646 shares of the company’s stock worth $127,060,000 after purchasing an additional 9,592 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.